Clariane Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Clariane de 104.1% y 5.1% por año respectivamente. Se prevé que el BPA crezca en un 1.9% al año. Se espera que la rentabilidad financiera sea de 0.9% en 3 años.

Información clave

96.1%

Tasa de crecimiento de los beneficios

83.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	23.2%
Tasa de crecimiento de los ingresos	5.4%
Rentabilidad financiera futura	1.3%
Cobertura de analistas	Low
Última actualización	26 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

ENXTPA:CLARI - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	5,887	24	733	792	2
12/31/2025	5,579	58	549	801	4
12/31/2024	5,293	-22	745	788	3
12/31/2023	4,996	-92	320	804	N/A
9/30/2023	4,865	-32	244	799	N/A
6/30/2023	4,735	28	168	794	N/A
3/31/2023	4,587	32	204	828	N/A
12/31/2022	4,438	36	239	862	N/A
6/30/2022	4,288	85	348	900	N/A
3/31/2022	4,212	92	330	870	N/A
12/31/2021	4,137	100	311	840	N/A
9/30/2021	4,047	76	279	818	N/A
6/30/2021	3,941	60	243	785	N/A
3/31/2021	3,857	50	259	790	N/A
12/31/2020	3,773	39	275	795	N/A
9/30/2020	3,728	57	310	765	N/A
6/30/2020	3,683	74	346	734	N/A
3/31/2020	3,648	94	393	750	N/A
12/31/2019	3,613	115	439	766	N/A
9/30/2019	3,542	117	352	687	N/A
6/30/2019	3,471	119	264	607	N/A
3/31/2019	3,404	121	188	492	N/A
12/31/2018	3,336	123	113	377	N/A
9/30/2018	3,280	152	139	371	N/A
6/30/2018	3,224	180	165	364	N/A
3/31/2018	3,177	172	181	375	N/A
12/31/2017	3,131	163	197	385	N/A
9/30/2017	3,091	150	N/A	353	N/A
6/30/2017	3,052	137	N/A	320	N/A
3/31/2017	3,017	134	N/A	314	N/A
12/31/2016	2,981	131	N/A	307	N/A
9/30/2016	2,880	87	N/A	296	N/A
6/30/2016	2,779	42	N/A	284	N/A
3/31/2016	2,676	50	N/A	264	N/A
12/31/2015	2,573	59	N/A	245	N/A
9/30/2015	2,553	77	N/A	271	N/A
6/30/2015	2,533	95	N/A	297	N/A
3/31/2015	2,378	78	N/A	272	N/A
12/31/2014	2,222	61	N/A	247	N/A
9/30/2014	1,938	44	N/A	186	N/A
6/30/2014	1,654	27	N/A	126	N/A
3/31/2014	1,505	28	N/A	122	N/A
12/31/2013	1,356	29	N/A	119	N/A
9/30/2013	1,286	29	N/A	118	N/A
6/30/2013	1,216	29	N/A	118	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CLARI sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1%).

Beneficios vs. Mercado: Se prevé que CLARI sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que CLARI sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (5.1% al año) de CLARI crezcan más despacio que el mercado de French (5.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 5.1% al año) de CLARI crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de CLARI sea baja dentro de 3 años (0.9%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Clariane Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 12% to €3.83

Price target decreased by 11% to €4.01

Price target decreased by 22% to €6.73

Price target decreased by 11% to €10.44

Consensus EPS estimates fall by 82%

Consensus EPS estimates increase by 18%

Recent updates

Clariane (EPA:CLARI) Takes On Some Risk With Its Use Of Debt

Price target decreased by 12% to €3.83

Clariane Confirms Rumor of Disposal of HAD/SSIAD Business in France

Price target decreased by 11% to €4.01

Full year 2023 earnings released

Elevation Healthcare Properties managed by Elevation Advisors signed an agreement to acquire Berkley Care Group Ltd from Clariane SE (ENXTPA:CLARI) for £207 million.

Investor sentiment deteriorates as stock falls 22%

Investor sentiment deteriorates as stock falls 18%

Clariane SE to Report First Half, 2024 Results on Jul 30, 2024

Is It Too Late To Consider Buying Clariane SE (EPA:CLARI)?

Price target decreased by 22% to €6.73

Investor sentiment deteriorates as stock falls 17%

These 4 Measures Indicate That Clariane (EPA:CLARI) Is Using Debt Extensively

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 31%

Clariane SE to Report Fiscal Year 2023 Results on Feb 28, 2024

Now 20% undervalued after recent price drop

Calculating The Fair Value Of Clariane SE (EPA:CLARI)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 11% to €10.44

Consensus EPS estimates fall by 82%

What Is Clariane SE's (EPA:CLARI) Share Price Doing?

First half 2023 earnings released

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Upcoming dividend of €0.25 per share at 3.3% yield

Consensus EPS estimates increase by 18%

Now 21% undervalued after recent price drop

At €6.98, Is It Time To Put Korian (EPA:KORI) On Your Watch List?

These 4 Measures Indicate That Korian (EPA:KORI) Is Using Debt Extensively

Consensus EPS estimates increase by 20%

Price target decreased by 11% to €20.50

Investor sentiment deteriorates as stock falls 19%

Consensus EPS estimates fall by 50%, revenue upgraded

Price target decreased by 8.2% to €21.63

Full year 2022 earnings released

Price target decreased by 7.4% to €21.94

A Look At The Fair Value Of Korian (EPA:KORI)

Korian (ENXTPA:KORI) acquired Grupo 5 Acción y Gestión Social, S.A. from Corpfin Capital Asesores, S.A., SGEIC and others.

Should You Think About Buying Korian (EPA:KORI) Now?

Korian to Report First Half, 2023 Results on Jul 27, 2023

Does Korian (EPA:KORI) Have A Healthy Balance Sheet?

Consensus forecasts updated

Price target decreased to €24.69

Investor sentiment deteriorated over the past week

Is There Now An Opportunity In Korian (EPA:KORI)?

Is Korian (EPA:KORI) A Risky Investment?

First half 2022 earnings released

Korian Appoints Philippe Lévêque as Director and Chairman of the Ethics, Quality and CSR Committee

Upcoming dividend of €0.35 per share

Why Korian (EPA:KORI) Could Be Worth Watching

Investor sentiment deteriorated over the past week

Consensus forecasts updated

High number of new directors

Korian Proposes Dividend

Consensus forecasts updated

We Think Korian (EPA:KORI) Is Taking Some Risk With Its Debt

Full year 2021 earnings: Revenues in line with analyst expectations

Price target decreased to €32.60

Price target decreased to €34.30

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Korian (EPA:KORI) Has A Somewhat Strained Balance Sheet

Icade Santé SAS completed the acquisition of 2 nursing homes in Le Teilleul and Notre-Dame-de-Sanilhac from Korian (ENXTPA:KORI) for €13 million.

Korian (EPA:KORI) Seems To Be Using A Lot Of Debt

Korian Provides Sales Guidance for the Year 2022

Consensus forecasts updated

First half 2021 earnings released: EPS €0.31 (vs €0.13 in 1H 2020)